| Compound Information | SONAR Target prediction |
| Name: | Aminocaproic acid |
| Unique Identifier: | Prest1193 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | C6H13NO2 |
| Molecular Weight: | 118.07 g/mol |
| X log p: | -1.394 (online calculus) |
| Lipinksi Failures | 0 |
| TPSA | 17.07 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 3 |
| Rotatable Bond Count: | 5 |
| Canonical Smiles: | NCCCCCC(O)=O |
| Generic_name: | Aminocaproic Acid |
| Chemical_iupac_name: | 6-aminohexanoic acid |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA448374 |
| Kegg_compound_id: | C02378 |
| Drugbank_id: | APRD00791 |
| Melting_point: | 205 oC |
| H2o_solubility: | 5.05E+005 mg/L |
| Logp: | 0.306 |
| Isoelectric_point: | 4.43 |
| Cas_registry_number: | 60-32-2 |
| Mass_spectrum: | http://webbook.nist.gov/cgi/cbook.cgi?Spec=C60322&Index=0&Type=Mass&Large=on |
| Drug_category: | Antifibrinolytic Agents; ATC:B02AA01 |
| Indication: | For use in the treatment of excessive postoperative bleeding. |
| Pharmacology: | Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid
lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be
exerted principally via inhibition of plasminogen activators and to a lesser degree
through antiplasmin activity. |
| Mechanism_of_action: | Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks
the binding of plasminogen to fibrin and its activation to plasmin. |
| Organisms_affected: | Humans and other mammals |
